Company Filing History:
Years Active: 2023
Title: Naomi Abe - Innovator in Antitumor Agents
Introduction
Naomi Abe is a prominent inventor based in Tsukuba, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the development of antitumor agents. Her innovative work focuses on targeting specific mutations in the epidermal growth factor receptor (EGFR), which is crucial in the treatment of certain malignant tumors.
Latest Patents
Naomi Abe holds 1 patent for her invention titled "Exon 18 and/or exon 21 mutant EGFR selective inhibitor." This patent describes an antitumor agent designed for treating patients with malignant tumors that express EGFR mutations, specifically targeting the G719X mutation of exon 18, E709X mutation of exon 18, and L861X mutation of exon 21. The antitumor agent comprises (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide or a salt thereof.
Career Highlights
Naomi Abe is currently associated with Taiho Pharmaceutical Company Limited, where she continues to advance her research in oncology. Her work has been instrumental in developing targeted therapies that improve treatment outcomes for patients with specific genetic mutations.
Collaborations
Naomi collaborates with Shinichi Hasako, who is also involved in research and development within the pharmaceutical industry. Their partnership enhances the innovative potential of their projects and contributes to the advancement of cancer treatment.
Conclusion
Naomi Abe's contributions to the field of antitumor agents exemplify the impact of targeted therapies in modern medicine. Her work not only addresses critical medical needs but also paves the way for future innovations in cancer treatment.